Drug profile · INN
mirvetuximab soravtansine
ELAHERE
mirvetuximab soravtansine (ELAHERE) is a tubulin inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX26
Patents linked 0
Pipeline programs 6
News articles 2
Drug details — mirvetuximab soravtansine
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
mirvetuximab soravtansine (ELAHERE) is a tubulin inhibitor.
Key facts
INN mirvetuximab soravtansine
Brand ELAHERE
Mechanism Tubulin inhibitor
Target Folate receptor alpha
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX26
Mechanism of action
Tubulin inhibitor
Primary target: Folate receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
AbbVie Secures FDA Approval for ImmunoGen's Elahere
Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere
FDA Approves Elahere: Expanded Use for Platinum-Resistant Ovarian Cancer
The FDA has approved Elahere for expanded use in patients with platinum-resistant ovarian cancer, marking a significant advancement in treatment options.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mirvetuximab soravtansine?
mirvetuximab soravtansine (ELAHERE) is a tubulin inhibitor.
What is the brand name for mirvetuximab soravtansine?
ELAHERE is a marketed brand name for mirvetuximab soravtansine. Check FDA Drugs@FDA for the current US label holder and prescribing information.